NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Description

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Conditions

Ischemia Reperfusion Injury, Myocardial Injury, Acute Kidney Injury

Talk to us

Study Overview

On this page

Study Details

Study overview

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Condition
Ischemia Reperfusion Injury
Intervention / Treatment

-

Contacts and Locations

San Francisco

Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States, 94115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Kaiser Permanente,

    Study Record Dates

    2025-06-30